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ABSTRACT 
Bladder cancer can be divided into non-muscle-invasive and muscle-invasive types. 
In the muscle-invasive type of bladder cancer, removal of the bladder and internal 
genitalia is the cornerstone of treatment. Treatment results can be improved with pre-
operative use of chemotherapy (neoadjuvant chemotherapy). 
In order to evaluate neoadjuvant chemotherapy associated adverse events and 
the effect on radical cystectomy related complications, we collected essential clinical 
and pathological data for all patients treated with or without neoadjuvant 
chemotherapy during 2005-2014 in Finland. The key findings were that patient 
selection for neoadjuvant chemotherapy is successful, most severe adverse events 
can be seen already after the first cycle and the use of neoadjuvant chemotherapy 
does not increase post-operative surgical complications. 
The other objective was to evaluate the potential of Positron emission 
tomography in combination with Magnetic resonance imaging in the evaluation of 
the primary staging of bladder cancer and treatment response to neoadjuvant 
chemotherapy. The key finding was that radical cystectomy cannot be avoided even 
when a complete radiological response is detected. 
KEYWORDS: Bladder cancer, Neoadjuvant chemotherapy, Adverse events, 
Positron emission tomography/Magnetic resonance imaging, Complications 
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ANTTI SALMINEN: Neoadjuvantti-kemoterapia lihasinvasiivisen 
virtsarakkosyövän hoidossa 
Väitöskirja, 91 s. 
Turun kliininen tohtoriohjelma 
Huhtikuu 2020 
TIIVISTELMÄ 
Virtsarakkosyöpä voidaan jakaa lihakseen invasoivattomaan ja lihakseen 
invasoivaan tyyppiin. Lihakseen invasoivan syövän hoidon kulmakivi on virtsarakon 
ja sisägenitaalien poistoleikkaus. Hoitotuloksia kyetään parantamaan leikkausta 
edeltävällä solusalpaajahoidolla ( neoadjuvantti-kemoterapia). 
Arvioimme neoadjuvantti-kemoterapiaan liittyviä hoidon aikaisia haittoja sekä 
kyseisen terapian vaikutusta radikaalileikkauksen jälkeisiin komplikaatioihin. 
Tutkimusta varten kerättiin keskeinen kliinis-patologinen data kaikista virtsarakon 
poistoleikkauksessa olleista potilaista Suomessa vuosina 2005–2014. Keskeisimmät 
löydökset ovat, että potilasvalinta onnistuu hyvin, vakavimmat solusalpaajahoitoihin 
liittyvät haitat tulevat ilmi heti ja neoadjuvantti-kemoterapia ei vaikuta leikkauksen 
jälkeisiin komplikaatioihin. 
Tutkimme myös positroniemissiotomografian ja magneettiresonanssikuvan-
tamisen tarkkuutta virtsarakkosyövän levinneisyyden ja neoadjuvantti-kemoterapian 
tehon arvioinnissa. Tärkein havainto on, että radikaalileikkaukselta ei voida välttyä, 
vaikka kuvantamisella arvioituna solusalpaajahoidon jälkeen ei ole syöpää havaitta-
vissa. 
AVAINSANAT: Virtsarakkosyöpä, Neoadjuvantti-kemoterapia, Lääkehaitat, Posi-
troniemissiotomografia/Magneettiresonanssikuvantaminen, Komplikaatiot 
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Abbreviations 
11C Carbon eleven 
AC Adjuvant chemotherapy 
ACCI Age-adjusted Charlson Comorbidity Index 
AE Adverse Event 
ASA American Association of Anaesthesiologists scale to evaluate fitness 
for surgical operations 
AUC Area under receiver operating characteristic curve  
BC Bladder cancer 
BT Bladder tumour 
CCI Charlson Comorbidity Index 
CG Cisplatin – gemcitabine 
CI Confidence interval 
CSS Cancer specific survival 
CT Computed tomography 
CTCAE Common Terminology Criteria of Adverse Events 
DCE Dynamic Contrast Enhancement 
dd Dose dense 
DWI Diffusion Weighted Imaging 
EPLND Extended pelvic lymph node dissection 
FDG 2-deoxy-2-[18F]fluoro-D-glucose 
FDR False discovery rate 
FWHM Full width at half maximum 
HR Hazard ratio 
LN Lymph node 
LND Lymph node dissection 
LNM Lymph node metastasis 
LRC Laparoscopic radical cystectomy 
MIBC Muscle-invasive bladder cancer 
MMT Multimodality treatment 
MRI Magnetic Resonance Imaging 
MVAC Methotrexate-vinblastine-doxorubicin-cisplatin 
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NAC Neoadjuvant chemotherapy 
NCIC Non continent ileal conduit 
NMIBC Non-muscle-invasive bladder carcinoma 
OCNB Orthotopic continent ileal neobladder 
OR Odds ratio 
OS Overall survival 
PAH Polycyclic aromatic hydrocarbon 
PET Positron Emission Tomography 
QoL Quality of life 
RARC Robot assisted radical cystectomy 
RC Radical cystectomy 
RCT Randomised clinical trial 
RT Radiation therapy 
SD Standard deviation 
SM Secondary malignancy 
SUVmax Standardised uptake value 
TNM Tumour Node Metastasis classification 
TUR-BT Transurethral resection of bladder tumour 
USPIO Ultra small paramagnetic particles of iron oxide 
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1 Introduction 
Radical cystectomy (RC) is not a new method for treating bladder cancer (BC). 
However, it did not become an established treatment method before problems with 
urinary diversion were resolved. The history of the early years covering diversion 
aspects is presented nicely by Pannek et al. (1998). During the 1950s, Bricker 
described a method for ileal conduit diversion still in use today (Bricker 1950). When 
combining two different organ systems, complications cannot be avoided. Early 
experiences of the nature of the complications of the Bricker method were described 
by Butcher et al. (1962) and the nature of the complications has not changed. 
Besides the RC operation itself containing many risks, one issue in BC is that 
without aggressive treatment, muscle-invasive bladder cancer (MIBC) leads to the 
death of the patient. Even when treated, nearly half of the patients die within five 
years (Abdollah et al. 2013). One way to improve cancer specific survival (CSS) is 
to add chemotherapy to the treatment. It can be given either before (neoadjuvant 
chemotherapy [NAC]) or after RC (adjuvant chemotherapy [AC]). Studies with 
NAC have been available for three decades, suggesting that for a proportion of NAC 
responders, bladder preserving strategies could be a viable option (Meyer et al. 
2014). However, a key element in selecting patients for bladder preserving strategies 
is staging accuracy. Metastases can be detected with fairly good accuracy by using 
conventional cross-dimensional imaging, but regional evaluation of especially the 
pelvic lymph nodes (LNs) remains challenging. 
This thesis is focused on the experience of NAC treatment in Finland. Treatment 
response to NAC was evaluated using 11C-acetate PET-MRI. A database was 
constructed to evaluate adverse events (AEs) during NAC treatment and the impact 
of NAC on post-operative surgical complications. Finally, risk factors to predict 
early post-operative mortality were identified using a machine learning 
methodology.
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2 Review of the Literature 
2.1 Epidemiology and risk factors 
Globally BC is recognised as the 6th most common cancer in males and 12th most 
common in total, with nearly 550,000 new diagnosed cases and causing nearly 
200,000 deaths per year (Bray et al. 2018). In Finland, BC statistics are combined 
with ureteral and pelvic carcinomas, with 1,343 new cases diagnosed in 2017 
(Syöpärekisteri 2017). In men, BC is the 4th most common, representing roughly 6% 
of newly diagnosed cancers (Syöpärekisteri 2017). Men are more commonly affected 
with distribution between the sexes at 4:1 (men:women) (Bray et al. 2018, 
Syöpärekisteri 2017). BC is also more common in Western societies (Bray et al. 
2018). Possibly this is due to longer life expectancy, but it also correlates with 
cigarette smoking, which is a known risk factor for BC (Brennan et al. 2000, Brennan 
et al. 2001). Both duration and quantity matter, with the threshold being 15-20 
cigarettes daily, making the pack years definition meaningful (Brennan et al. 2000, 
Brennan et al. 2001). Cessation of smoking reduces risk, but even after 25 years of 
abstinence, the risk level does not reach that of a never-smoker (Brennan et al. 2000, 
Brennan et al. 2001). Other identified risk factors include exposure to certain 
chemical agents (mineral oils, diesel engine fumes, painting, barber and hairdresser 
products, aromatic amines and polycyclic aromatic hydrocarbon compounds (PAHs) 
(Rushton et al. 2010). Similar to cigarette smoking, occupational exposure is a risk 
factor that can be influenced, leading to risk reduction. 
Radiation therapy (RT) has been shown to increase the risk of secondary 
malignancies (SM) on a population level (Wang et al. 2019). With modern 
technologies, RT seems to be better tolerated and less harmful; even if SM is 
detected, it is seldom lethal (Zelefsky et al. 2012). 
Chronic infection is a solid risk factor, but the trend in the most commonly 
known infectious agent, the bilharzia parasite, seems to be in decline (Salem & 
Mahfouz 2012). 
Antti Salminen 
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2.2 Diagnosis and staging 
With visible haematuria the risk of bladder tumour is 19% (Khadra et al. 2000). The 
standard diagnostic pathway comprises of urine sample, urine cytological 
evaluation, cystoscopy and imaging (Babjuk et al. 2019). Staging follows the Tumor 
Node Metastasis (TNM) classification (Brierley et al. 2017) as demonstrated in 
Table 1. 
Table 1. TNM classification of bladder tumour (8th edition). 
T - Primary Tumour N - Regional Lymph Nodes 
Tx Primary tumour cannot be assessed Nx Regional lymph nodes cannot be 
assessed 
T0 No evidence of primary tumour N0 No regional lymph node metastasis 
Ta Non-invasive papillary carcinoma N1 Metastasis in a single lymph node in the 
true pelvis (hypogastric, obturator, external 
iliac, or presacral) 
Tis Carcinoma in situ: “flat tumour” N2 Metastasis in multiple regional lymph 
nodes in the true pelvis (hypogastric, 
obturator, external iliac, or presacral) 
T1 Tumour invades subepithelial connective 
tissue 
N3 Metastasis in a common iliac lymph 
node(s) 
T2 Tumour invades muscle  
T2a Tumour invades superficial muscle (inner 
half) 
M - Distant Metastasis 
T2b Tumour invades deep muscle (outer half) M0 No distant metastasis 
T3a Tumour invades perivesical tissue 
microscopically 
M1a Non-regional lymph nodes 
T3b Tumour invades perivesical tissue 
macroscopically (extravesical mass) 
M1b Other distant metastasis 
T4a Tumour invades prostatic stroma, seminal 
vesicles, uterus or vagina 
Tumour invades prostatic stroma, seminal 
vesicles, uterus or vagina 
T4b Tumour invades pelvic wall or abdominal wall  
2.2.1 Histopathology and cytology 
Most bladder tumours (BT) (75%) are non-invasive (Burger et al. 2013). All MIBC 
tumours are however high-grade tumours and strict pathological classifications that 
are useful in non-muscle-invasive bladder carcinoma (NMIBC) have no or little 
impact on prognosis in MIBC (Jimenez et al. 2000). Urine cytology alone has no use 
in MIBC diagnostics as described in the DETECT 1 study (Tan et al. 2019). 
Histopathological evaluation was updated in 2016 (Humphrey et al. 2016). It is 
clear that while the vast majority of BTs are urothelial in origin, there is an 
abundance of subtypes or histopathological variances especially in invasive tumours 
Review of the Literature 
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(Humphrey et al. 2016). Currently ten different subtypes have been identified: 
Nested, Microcystic, Micropapillary, Lymphoepithelioma-like, Plasmacytoid, 
Sarcomatoid, Giant cell, Poorly differentiated, Lipid rich and Clear cell (Humphrey 
et al. 2016). Evaluation of these subtypes is vital, since they often behave 
aggressively and may mimic the metastasis of another primary tumour, as in the 
plasmocytoid variant (Wang & McKenney 2019). 
2.2.2 Cystoscopy and transurethral resection 
Ultimately, BT visualization is done with cystoscopy. It is best performed in an 
outpatient clinic with flexible videoscope under local anaesthesia (Krajewski et al. 
2017). However, visualisation of tumour invasiveness is not reliable in cystoscopy. 
If BT has been visualised by accident on imaging studies done for other purposes, 
cystoscopy can be left undone and the patient can go straight to the operating room 
for resection (Witjes et al. 2017). 
As a diagnostic procedure transurethral resection of a bladder tumour (TUR-BT) 
specimen should contain muscle to reveal possible invasion. This is best done by 
separate sample of the tumour bed, or in the absence of muscle in the specimen, a 
re-TUR-BT is advisable (Witjes et al. 2017). 
2.2.3 Cross-sectional imaging 
Computed tomography (CT) is an anatomical imaging method, reliable, fast, and 
easily accessible. CT-urography is accurate in visualisation of BT with accuracy of 
92.8% (Capalbo et al. 2015). An adequate imaging protocol has a key role in BT 
identification – BTs should have enhancement and are more likely focal than 
expressing diffuse bladder wall enhancement (Raman & Fishman 2017). However, 
with a macroscopic imaging method like CT, microscopic invasion through the 
bladder wall is impossible to detect and CT’s main utility is to visualise local spread 
and distant metastases (Witjes et al. 2017). 
In LN evaluation, CT also relies on the size of the LN, which is problematic, 
since LN metastases (LNM) may also be present in normal size LNs. The accuracy 
of CT in LNM detection is approximately 83%, with poor sensitivity, 53% (Horn et 
al. 2016). 
Magnetic resonance imaging (MRI) is a radiation free, non-invasive, safe 
imaging modality (Sammet 2016). The use of intravenous contrast medium is 
optional and tissue contrast can be modified with different sequences. The diagnostic 
performance (sensitivity and specificity) of MRI in MIBC evaluation has been 
reported to be 0.92 (95% confidence interval [CI] 0.88–0.95) and 0.87 (95% CI 0.78–
0.93) in a systematic review and meta-analysis (Woo et al. 2017). Overall accuracy 
Antti Salminen 
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has been reported in a prospective MRI study utilising dynamic gadolinium contrast 
enhancement (DCE). The study enrolled 122 patients and overall accuracy in MIBC 
evaluation was 74% (Daneshmand et al. 2012). 
In LN evaluation, functional applications, such as diffusion weighted imaging 
(DWI) improve detection of LNM compared to standard cross-sectional imaging 
(Thoeny et al. 2014). Overall sensitivity is 56% and specificity 87% in a systematic 
review and meta-analysis (Woo et al. 2018). Daneshmand et al. had 27/122 (22%) 
LNM-positive patients. The overall accuracy of DCE-MRI in LN positivity 
evaluation with correlation to histopathology was 80.3%. However, the false 
negative rate was as high as 59% (Daneshmand et al. 2012). 
2.2.4 Positron emission tomography 
Positron emission tomography (PET) is accompanied by an anatomical imaging 
method, such as CT. In urology PET has gained popularity, but current evidence 
does not support routine use in BC diagnostics (Rauscher et al. 2018). Although 
pooled sensitivity 0.82 (95% CI, 0.75 to 0.88) and pooled specificity 0.92 (95% CI, 
0.87 to 0.95) values have been reported by Zhang et al. 2015, PET is considered most 
useful in search of metastases; that is to select patients for NAC and to avoid RC on 
patients with metastases (Kibel et al. 2009). In LN imaging, the performance of PET-
CT relies too much on LN size and is not recommended (Pichler et al. 2017). One 
critical issue in PET imaging is that the most commonly used 2-deoxy-2-[18F]fluoro-
D-glucose (18F-FDG) is secreted in urine, making its use especially in BC diagnostics 
problematic (Agarwal et al. 2016). 
Other tracer options in BC diagnostics include carbon-eleven (11C)-choline and 
11C-acetate which are not secreted in urine. Preliminary results with 11C-choline were 
promising in BT evaluation, but LN evaluation left room for improvement in a 27-
patient prospective series by Picchio et al. 2006. Another small study nearly a decade 
later showed similar results with a sensitivity of 42% and specificity of 84% in LN 
imaging (Brunocilla et al. 2014). 
11C-acetate has been evaluated in two prospective studies (Schöder et al. 2012, 
Vargas et al. 2012) with a total of 33 patients. Schöder et al. reported promising 
results, but underlined interpretation difficulties if prior instillation therapies to the 
bladder had been used. Vargas et al. verified this finding and reported similar results 
with 11C-acetate PET-CT vs. MRI vs. CT alone. 
11C-choline PET-CT and 11C-acetate PET-CT have been compared in one 14-
patient series, with similar performance (Orevi et al. 2012). The slight difference was 
that the standardised uptake value (SUVmax) was higher in BT with 11C-choline and 
higher in LN with 11C-acetate (Orevi et al. 2012). Since BT evaluation eventually 
relies on histopathological diagnosis, the special emphasis of 11C-acetate and 11C-
Review of the Literature 
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choline has been in LN imaging. A systematic review and meta-analysis by Kim et 
al. (2018) sums up PET-CT’s capability in LN imaging with these two tracers nicely: 
sensitivity is low and specificity moderate.  
PET has been combined with MRI in only one study using 18F-FDG as a tracer 
(Rosenkranz et al. 2017).  
2.3 Surgical treatment 
Most bladder tumours are local and organ-preserving strategies may be utilised 
(Burger et al. 2013, Babjuk et al. 2019). In small non-invasive tumours even an 
outpatient procedure may be a viable option (Rivero Guerra et al. 2018). In MIBC 
this is not the case. 
2.3.1 Transurethral resection of bladder tumour (TUR-BT) 
Surgery starts with endoscopic procedures. In the case of MIBC the strategy of 
performing TUR-BT differs from that of NMIBC. There are three strategies: 
1. Total removal of bladder tumour and possible satellites with intent to cure 
2. Adequate biopsy material for identification of tumour histology and depth 
of invasion 
3. Palliative coagulation of bleeding tumours in patients unfit for radical 
surgery. 
In MIBC patients TUR-BT alone is mainly a diagnostic tool; as a monotherapy 
modality for highly selected patients, it has been suggested in only a few studies 
(Herr 1987, Solsona et al. 1992, Solsona et al. 2010). However the guideline 
recommendation is strong to avoid TUR-BT as a sole treatment (Witjes et al. 2017). 
Surgical complications of TUR-BT are common with roughly 30% prevalence 
and include haematuria, infection and bladder perforation (Avallone et al. 2017). 
Death is however rare (0.1–0.5%) (Liem et al. 2018, Avallone et al. 2017). Bipolar 
resection may be safer than monopolar resection (Avallone et al. 2017, Bolat et al. 
2016, Bolat et al. 2018, Mahmoud et al. 2019). Although the total number of 
complications may be greater in bipolar TUR-BT, severe complications are more 
often seen with monopolar TUR-BT (Liem et al. 2018). Adding intraoperative 
instillation of a chemotherapeutic agent is not beneficial with MIBC patients and 
thus chemotherapy-related complications can be avoided (Nieuwenhuijzen et al. 
2003, Elmamoun et al. 2014). 
Antti Salminen 
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2.3.2 Radical cystectomy and pelvic lymph node dissection 
In NMIBC patients RC may be a viable option for cancer treatment, but not the 
primary option (Babjuk et al. 2019). In MIBC RC should follow NAC in eligible 
patients (Witjes et al. 2017). Standard RC consists of removal of the bladder and 
distal ureters accompanied by adequate LN dissection. The operation includes 
removal of the prostate and seminal vesicles in men and removal of the urethrae, 
uterus and anterior wall of the vagina in women (Stenzl et al. 2005). Recently, 
however, a prostate-sparing method has been described as an alternative for 
maintaining continence and sexual function (Mertens et al. 2014). In females, 
continent neobladder with pelvic organ preservation has been studied in systematic 
review with a positive functional outcome (Veskimae et al. 2017). Currently, organ 
preservation techniques are not as strongly recommended in women as in men and 
patient selection is of critical value (Witjes et. al 2017). 
RC is accompanied by pelvic lymph node dissection (PLND). The standard 
PLND boundaries are the distal common iliac artery proximally, the genitofemoral 
nerve laterally, the inguinal ligament distally and the bladder wall medially (Herr et 
al. 2004). The extended (EPLND) template includes the sacral nodes and the 
proximal boundary is aortic bifurcation or in some instances even slightly above 
(Herr et al. 2004). EPLND is normally suggested for better staging (Simone et al. 
2013). The template follows the lymphatic spread pathways described by Roth et al. 
(2010). Even in the presence of micro metastases or known positive LNs, cure is 
possible (Karl et al. 2009). But, although staging may be more accurate by expanding 
the LN template to extended, only the rate of complications increases (Gschwend et 
al. 2019) without improvement in CSS (Zehnder et al. 2011). 
In Finland, RCs have mainly been done as open surgery. Laparoscopic RC 
(LRC) and robotic-assisted laparoscopic RC (RARC) have gained popularity as less 
invasive methods and have been shown to be equal in terms of oncological outcome 
(Kim et al. 2016). The CORAL study is a prospective RCT with 60 patients 
randomised to RC, LRC or RARC. There was no difference in 5-year surveillance 
(Khan et al. 2019). A recent systematic review and meta-analysis shows a similar 
tendency (Albisinni et al. 2019). More data is awaited from the Dutch RACE-study 
which should be completed in the near future (Wijburg et al. 2018). 
Removal of the bladder requires urinary diversion. Various techniques for 
urinary diversion have been described (Hautmann et al. 2007). Each has its pros and 
cons and complication profiles of different diversion methods have been evaluated 
recently by Faba et al. (2018) and Anderson & McKiernan (2018). In Finland mainly 
non-continent ileal conduit (NCIC) and orthotopic continent ileal neobladder 
(OCNB) have been used. 
Review of the Literature 
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2.4 Chemotherapy 
One particular problem with MIBC is that staging is inaccurate (Shariat et al. 2009, 
Türker et al. 2012). Differentiation of T2b or T3a tumours is virtually impossible 
with imaging. In order to improve CSS, NAC is suggested for all MIBC patients 
eligible for platinum (Witjes et al. 2017).  
2.4.1 Neoadjuvant chemotherapy 
NAC should be platinum-based (Witjes et al. 2017, Chang et al. 2017). Although 
NAC treatment for BC started as early as in the 1980s, it was not until 2006 that the 
cisplatin-gemcitabine (CG) regimen was introduced (Hermans et al. 2017). In 
Finland methotrexate-vinblastine-doxorubicin-cisplatin (MVAC) has not been 
widely utilised, but CG started in Turku 2008 and has gained popularity. All key 
randomised clinical trials (RCTs) have however been done with other regimens than 
CG (Hermans et al. 2017, Yin et al. 2018). Only three prospective studies with CG 
exist (Osman et al. 2014, Khaled et al. 2014, Iyer at al 2018) accompanied by one 
systematic review covering seven retrospective studies and one phase II study (Yuh 
et al. 2013). Despite the modality, NAC has been shown to improve survival in study 
populations (Yin et al. 2018). These results do not necessarily correlate with daily 
clinic populations, where overall survival (OS) benefit could not be shown (Hanna 
et al. 2018). But NAC is strongly recommended by the guidelines as a standard of 
care in MIBC (Witjes et al. 2017). The overall efficacy of NAC is presented in Table 
2. 
Table 2.  NAC + RC compared to RC alone. Adopted from Advanced Bladder Cancer (ABC) 
Meta-analysis collaboration (Collaboration A.B.C.A.M-a 2005). 
Modality OS improvement CSS improvement 
SAP -5% (-14–4%) -5% (-16–7%) 
PBC 5% (2–9%) 9% (5–12%) 
SAP = Single agent platinum; PBC = Platinum based combinations 
Common adverse events (AEs) caused by platinum compounds include 
haematological, renal, vascular, ototoxic and neural damage (Oun et al. 2018). 
Nearly all (90%) patients have at least grade 1 AEs (Iyer et al. 2018). In the 
comparison of different NAC regimens, Grade 3 to 4 toxicity rates for ddMVAC 
(32%) and CG (44%) have been reported as significantly lower than for the classic 
MVAC regimen (55%) (Hermans et al. 2018). A CG NAC dd regimen however 
seems to increase AEs (Anari et al. 2018). The NAC regimen typically used in 
Finland contains three or four cycles of CG with three weeks interval compared to 
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the dd protocol executed in two weeks (Anari et al. 2018). The standard dosing of 
one cycle is  
Day 1: cisplatin 75mg / m² + gemcitabine 1000mg / m² 
Day 8: gemcitabine 1000mg / m² 
2.4.2 Adjuvant chemotherapy 
Five-year survival in MIBC for organ confined disease is roughly 70%, but with 
local spread to LNs only 36% (SEER). LN-positive BC is seen in 18-28% of MIBC-
patients (Stein & Skinner 2006). While LN positivity has a clear impact on survival, 
the majority of MIBC patients are LN-negative and in organ confined disease RC 
only gives comparable results to NAC + RC (Malmström et al. 1995). 
AC has the benefit of avoiding unnecessary chemotherapy, since NAC is always 
started based on more-or-less inaccurate staging (Hermans et al. 2017). However, 
30% of RC patients may suffer from surgery related complications that prohibit the 
use of AC (Donat et al. 2009). 
Node-positive patients have been shown to benefit most from AC in terms of 
progression-free survival (Leow et al. 2014). However, this does not affect OS 
(Sternberg et al. 2015). This may be due to the fact that some LN+ patients may be 
cured with surgery alone (Zehnder et al. 2014). At the moment, guideline 
recommendations suggest AC for pT3/4 and/or pN+ patients, who have not received 
NAC (Witjes et al. 2017).  
2.4.3 Other treatment options 
Radiotherapy (RT) of the bladder is mainly reserved for older frail people unfit for 
surgery (MacHaffie et al. 2016). A combination of chemotherapy and RT has worse 
results compared to NAC + RC, but for patients who tolerate this treatment, organ 
preservation is possible (Lin et al. 2018). The rationale is to improve quality of life 
(QoL) with organ preservation and thus it is not suggested for patients with poor 
bladder function (MacHaffie et al. 2016). One method to effectively reduce bowel 
irradiation is adaptive radiotherapy (Tuomikoski et al. 2011). 
In multimodality treatment (MMT), TUR-BT is accompanied by chemotherapy 
and radiation therapy (RT) with special emphasis on bladder preservation and QoL 
(Ploussard et al. 2014). MMT seems to be comparable to RC (García-Perdomo et al. 
2018, Kulkarni et al. 2017). Although MMT seems to be comparable to RC, the 
possibility to salvage RC should be discussed already when deciding treatment 
strategy (Leow et al. 2019). Palliative purposes are not in the context of this thesis. 
The current medical therapy comprises platinum-based chemotherapy. 
Immunological programmed cell death protein 1 / ligand 1 (PD-1) / (PD-L1) 
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checkpoint inhibitors have shown potential in a metastatic setting (Lattanzi & Balar 
2019). With this promising experience, these immunological drugs have also been 
started to be studied in NAC setting. 
One study (PURE-1) evaluated pembrolizumab in a neoadjuvant setting for 
MIBC patients with variant histology (Necchi et al. 2019). Lymphoepithelioma-like 
and squamous cell bladder carcinoma patients were most likely to benefit; a similar 
response was not seen in other types of MIBC (Necchi et al. 2019). 
Two studies are recruiting platinum-ineligible patients [NCT03234153 
(durvalumab and tremelimumab) and NCT03520491 (nivolumab and ipilimumab)]. 
The NCT03732677 “NIAGARA” study is designed to add durvalumab to 
perioperative medical treatment [Durvalumab + CG (NAC) and Durvalumab (AC)]. 
Results are awaited in 2021-2025. 
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3 Aims 
The specific aims of the thesis were: 
1) To evaluate NAC treatment response with novel 11C-acetate PET-MRI 
with surgical pathology as a reference. 
2) To evaluate AEs during NAC treatment and identify possible risk factors 
for poor tolerance. 
3) To analyse the effect of NAC on early post-operative complications of 
RC. 
4) To identify potential risk factors predicting early post-operative mortality 
after RC using a deep learning methodology. 
 
 21 
4 Materials and Methods 
4.1 PET-MRI (Study I) 
The study (Acetate PET-MRI and Biomarkers in Bladder cancer, ACEBIB) was 
carried out as a prospective multicentre study. The participating centres were Turku 
University Hospital, Helsinki University Hospital and Tampere University Hospital. 
The ethical committee of the Hospital District of Southwest Finland approved the 
study. The study was registered at ClinicalTrials.gov (NCT01918592). The study 
was conducted in compliance with the current revision of the Declaration of Helsinki 
guiding physicians and medical research involving human subjects. Patient 
recruiting was organised in urological outpatient units in all participating hospitals. 
Inclusion and exclusion criteria are presented in Table 3. 
Table 3. Inclusion and exclusion criteria in the ACEBIB study. 
Inclusion criteria Exclusion criteria 
Age: 18 to 85 years old History of serious cardiovascular, liver or kidney 
disease 
Language spoken: Finnish or Swedish Uncontrolled serious infection 
Invasive or locally advanced bladder cancer 
based on cystoscopical evaluation. 
Contraindications for MRI (cardiac pacemaker, 
intracranial clips, etc.) 
Mental status: Patients must be able to 
understand the meaning of the study 
Patient refusing radical cystectomy or 
chemotherapy 
Informed consent: The patient must sign the 
appropriate Ethical Committee approved 
informed consent documents in the presence of 
the designated staff 
Intravesical Bacillus Calmette-Guerin 
instillations within 6 months 
 
The PET-MRI imaging was performed using the Philips Ingenuity PET-MRI system. 
Initially, data for attenuation correction was obtained followed by T2-weighted turbo 
spin echo and T1-weighted anatomic imaging in the axial, sagittal and coronal 
directions. Diffusion weighted imaging (DWI) was obtained with single-shot spin-
echo echo-planar imaging followed by gadolinium-enhanced T1-weighted imaging. 
After acquiring the MRI data, the patient’s table was rotated to continue with PET 
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imaging. Two table positions covering the whole pelvis were acquired. The sinogram 
data was corrected for dead time, decay and photon attenuation and reconstructed in 
a 256 x 256 matrix. Image reconstruction followed a fully 3-D maximum-likelihood 
ordered subset. The expectation maximum algorithm incorporated random and 
scatter correction with 2 iterations and 28 subsets. The final in-plane full width at 
half maximum (FWHM) was about 6 mm. 
The remote-controlled and automated synthesis of 11C-acetate used in PET 
scan was prepared from 11C carbon dioxide and methyl magnesium bromide with 
the radiochemical purity of the final product ≥98%. The synthesis method 
followed the method originally described by Pike et al. (1982). A detailed 
description of the synthesis is available as Quality Document MET4500 on the 
PET Centre Intranet. 
Bladder filling was standardised by catheterisation. Before imaging, the bladder 
was emptied and filled with 100cc sterile saline. After PET, the bladder was emptied, 
radioactive urine was disposed of and the bladder was filled with 100cc sterile saline. 
After imaging, the bladder was emptied and the catheter removed. The isotope was 
injected via a G20 i.v. cannula, which was inserted into the v. cephalica of the non-
dominant hand. The activity of the isotope was documented to ensure adequate 
image quality. 
All images were evaluated by experienced radiologists and isotope physicians 
using the template described in Study I for LN areas. 
After imaging, a complete TUR-BT was executed by an experienced urologist in 
the treating hospital in primary staging and the RC & EPLND pathology was 
analysed to estimate the NAC treatment response. The pathology specimen was 
investigated by an experienced uropathologist. Imaging results were compared to the 
pathology, which served as a ground truth. 
4.2 Finnish Radical cystectomy database (Study II 
& III) 
The database is a secure Internet application created for the collection of essential 
clinic-pathological data of RC patients operated on all Finnish hospitals. Basic 
requirements and technical requirements – provided by Turku University – are 
presented in Table 4. 
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Table 4.  Basic and technical requirements of the Finnish Radical Cystectomy Database. 
Basic requirements Technical requirements 
Patient privacy and confidentiality are protected Web Server 
Data integrity is maintained URL Domain 
Data input is user-friendly Python 3.3 
Application is flexible and maintainable Django 1.6 
Application is secured for authorised users only PostgreSQL 9.3.4 
Access is controlled with user privileges1 PyCharm 3.1 
1Standard user can see only own centre’s data. Main researcher can compare different centres. 
System security was vital. All inputted data was coded and no personal data was 
collected. Authentication and authorisation of users were implemented to preserve 
patient confidentiality, which was not jeopardised in any way. To prevent attacks 
and unauthorised disclosure of data that could risk the integrity and availability of 
the data, the following security considerations were applied. All users who had 
access to the system needed a valid username and password. The use of the system 
was controlled, with authorised users having explicit privileges and able to perform 
only specific tasks. Moreover, during the development of the web application, 
concepts such as CSRF (Cross Site Request Forgery), SQL injection, input validation 
and output escaping, among others were taken into account to avoid security holes 
and different types of tests were performed during development and before 
deployment allowing security assessment of the web application. 
Patients were identified by their diagnosis number (ICD-10) [C67*] or NCSP 
(Nordic Classification of Surgical Procedures) code [KCC*]. Data collection involved 
all 16 hospitals that performed RCs in Finland during the observation period covering 
2005–2014 and was inputted retrospectively. Study II was designed to evaluate AEs 
during NAC treatment and identify potential risk factors forecasting AEs during NAC 
treatment. NAC-associated AEs were reported using Common Terminology Criteria 
for Adverse Events (CTCAE) v. 5.0 2018 (available on the Internet 
https://ctep.cancer.gov/protocoldevelopment/.../ctcae_v5_quick_reference_5x7.pdf). 
Study III was designed to evaluate the effect of NAC on early post-operative 
complications of RC. Complications were reported by Clavien classification (Dindo 
et al. 2004). The collected data parameters are presented in Table 5. 
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Table 5.  Complete list of variables collected in the Finnish radical cystectomy database. 
Type of Data Variable Measure 
Basic characteristics Date of birth  
 Gender Male / Female 
Height cm 
Weight kg 
Smoking, status current, former, never 
Smoking, quantity pack years 
ASA class  
CCI  
Body mass index kg/m2 
Centre  
Tumour characteristics TUR-BT histology  
TUR-BT grade WHO 1973, WHO/ISUP 2004 
TUR-BT T-category  
cTNM  
RC Histology  
RC TN category  
Neoadjuvant chemotherapy Start date  
Regimen  
Number of cycles  
Clinical response  
Adverse events CTCAE v.5 
Radical cystectomy Date of surgery  
Haemoglobin mg/l 
Creatinine µmol/l 
Surgeon  
Type of diversion  
Duration minutes 
Blood loss ml 
Transfusions number of units 
Post-operative care In-hospital stay days 
Transfusions number of units 
Anticoagulation prophylaxis Type, duration (days) 
Adjuvant therapy Chemotherapy (if given) Regimen, cycles 
Radiation (if given) Dose, (Gy) 
Complication / 
Adverse events 
Treatment phase NAC, RC, post-operative 
Date  
Severity Grade (Clavien class) 
Affected organ system  
Materials and Methods 
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4.3 Machine-learning methodology to predict 
mortality (Study IV) 
A machine-learning project was created for identification of potential pre-operative 
risk factors to predict early post-operative mortality. The pre-operatively available 
RC data was utilised. After random division of the data into testing data (33.3%) and 
training data (66.7%), the model-building was done in two stages. In the first stage, 
the training data was used to build 100 lasso logistic regression models using 10-fold 
cross-validation to minimise the cross-validation error. In the second stage, variables 
for the final model were added one by one based on the frequency of their occurrence 
in these 100 models until the area under the receiver operating characteristic curve 
(AUC) in the training data no longer increased. In the second stage, 10-fold cross-
validation was used. The ASA class and age-adjusted Charlson co-morbidity index 
(ACCI) were divided into low and high groups: ASA classes into 1–2 and 3–4, ACCI 
into 0–4 and 5–12. 
4.4 Statistical analysis 
Study I Performance of 11C-acetate PET-MRI for BT staging was evaluated in 15 
treatment-naïve patients. The classification was performed in a binary class for 
clinical relevance: benign + NMIBC (Ta, Tis, T1) vs MIBC (T2-T4). NAC response 
was evaluated for five patients who underwent RC and EPLND. LNs were evaluated 
by patient level and with regional classification (10 regions of interest, in total 50 
regions) between benign vs. malignant LNs. Sensitivity, specificity and accuracy 
were calculated. Ninety-five percent CI for AUC values were calculated from 100 
000 bootstrap samples using the trapezoid rule. Standardised uptake value (SUV) 
measurements were compared using the Bonferroni multiple comparison test 
(DeGroot & Schervish 2011). The statistical analysis was performed using 
MATLAB (version r2013a, The MathWorks Inc, Natick, MA). 
Study II Spearman correlation between AEs and 22 clinical variables was 
calculated. P-values were corrected for multiple testing by controlling false 
discovery rate (FDR) using the Benjamini-Hochberg method (Benjamini & 
Hochberg 1995). Statistical analysis was done using R (R Core Team 2017).  
Study III The material was divided into three cohorts and different analyses 
were applied to the cohorts to comprehensively analyse the effect of NAC on post-
operative complications. 
Simple binary logistic regression and multivariable logistic regression analyses 
were utilised in Entire cohort analyses, where all RC patients were compared to 
NAC + RC patients. 
The Neoadjuvant era cohort was first analysed using a simple logistic regression 
model. Next, a multivariable stratified logistic model with propensity score was 
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calculated using the variables patient age, gender, BMI, ASA class, CCI score, 
tumour histology, stage and grade (WHO 1973 or 2004) from the TUR-BT 
specimen, hospital volume, and glomerular filtration rate. The propensity score was 
categorised into five groups based on the quintiles and that variable was used in the 
multivariable stratified logistic model as a stratum. The results of the models were 
also adjusted for volume of hospital (three categories: high, medium and low), CCI 
score and age. 
The third cohort was cognitively matched – patients fit for NAC based on 
characteristics but operated on before NAC was initiated in Finland – compared to 
NAC patients. A simple logistic regression model and multivariable stratified 
logistic regression analysis were performed. 
All analyses were made for all complications (Clavien grades 1–5), severe/major 
complications (Clavien grades 3–5) and deaths (Clavien grade 5). Continuous 
variables were characterised using means and standard deviations (SD) or range of 
values, and in the case of categorical variables, frequencies and percentages were 
used. The results of the analyses were quantified using odds ratios (ORs) with 95% 
CI. P-values less than 0.05 were considered statistically significant. Statistical 
analyses were carried out using the SAS system for Windows, Version 9.4 (SAS 
Institute Inc., Cary, NC, USA). 
Study IV Twenty-two pre-operatively available variables were individually 
tested to reveal correlation with variable and early (90d) post-operative mortality. 
Numerical variables were tested with the Wilcoxon rank sum test and categorical 
variables with the chi-squared test. The false discovery rate (FDR) to eliminate false 
correlations was adjusted using the Benjamini–Hochberg procedure (Benjamini & 
Hochberg 1995). 
Hazard ratios (HR) for each variable in the training data were estimated using 
the Cox proportional hazards regression. The Cox proportional hazards regression in 
the testing data was done using R package survival (R Core Team 2017) and the 
model-building and statistical analysis were performed using the R statistical 
computing environment (version 3.4) (R Core Team 2017). The R package glmnet 
was used for logistic regression model with lasso regularisation (Friedman et al. 
2010, Therneau et al. 2000, Therneau 2015). 
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5 Results 
5.1 PET-MRI in treatment response evaluation 
(Study I) 
Eighteen patients were enrolled, 15 in primary tumour evaluation and 5 in NAC 
treatment response evaluation. Two patients attended both phases of the study. 
Despite careful and hygienic catheterisation, three patients developed urinary tract 
infections. Cannulation was successful on all patients. NAC-associated AEs were 
not documented and it was not necessary to make dose adjustments to anticancer 
drugs or postpone cycles. Basic characteristics of the study population are presented 
in Table 6. 
Table 6.  Study population in the ACEBIB study. 
 Primary tumour NAC response 
Number of patients 15 5 
Gender (male / female) 13 / 2 5 / 0 
Age (Years) Mean (range) 67 (55–79) 65 (57–69) 
ASA Mean (range) 2 (1-3) 2 
BMI (kg/m2) Mean (range) 27 (23–31) 26 (23–30) 
Primary staging (n=15): 
All primary tumours were urothelial cancers and demonstrated positive uptake of 
11C-acetate. The median maximum standardised uptake value (SUVmax) was 2.9 
(range, 1.3–4.7). There was no difference between the SUVmax of MIBC versus 
NMIBC. The sensitivity, specificity, accuracy and the AUC (95% CI) values of 11C-
acetate PET-MRI for the detection of MIBC (primary BT staging) were 1.00, 0.69 
and 0.73, and 0.85 (0.55–1.00). None of the MIBC patients were understaged. 
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Evaluation of therapy response to NAC (n=5): 
Compared to histopathology, 11C-acetate PET-MRI correctly staged three patients, 
overstaged one and understaged one patient. True negative findings in BT were 
reported in two patients and true positive in one patient. The performance of PET-
MRI in NAC treatment response evaluation is presented in Table 7. 
Table 7.  PET-MRI in NAC treatment response evaluation compared to RC histopathology (n=5). 
Patient PET-MRI RC 
 Primary 
tumour (T) 
LNM1 Primary 
tumour 
LN 
ntot / n+2 
1 T0 Yes T0 27 / 0 
2 T4 Yes T2 42 / 3 
3* T0 No T3 27 / 9 
4 T0 No T0 43 / 0 
5 T3 No T2 36 / 0 
    175 / 12 
1LNM = Lymph node metastasis present yes / no; 2LN ntot / n+ = total amount of Lymph nodes 
removed / cancer-positive lymph nodes *The patient had bilateral hip prostheses, which distorted 
the image quality 
Lymph node metastasis detection: 
The sensitivity, specificity and accuracy of 11C-acetate PET/MRI for the detection 
of LN metastases on the predetermined 10 nodal areas were 0.2, 0.96, 0.88, 
respectively, and the AUC (95% CI) value was 0.58. The corresponding values on a 
patient level were 0.5, 0.67, 0.6, and 0.58. 
5.2 Adverse events during NAC treatment (Study 
II) 
Thirty-one percent of MIBC patients were assigned to NAC during the observation 
period. The total number of patients in the final analysis was 229. Basic 
characteristics of the study population are presented in Table 8. 
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Table 8.  Basic characteristics of the study population in NAC-related AEs. 
Variable Description   
Gender Male 
Female 
N (%) 189 (83) 
40 (17) 
Age Years Mean (range) 65 (44–81) 
BMI kg / m2 Mean (range) 26 (16–39) 
ASA 1–2 
3–4 
Unknown 
N (%) 96 (42) 
105 (46) 
28 (12) 
ACCI  Mean (range) 4 (1–10) 
NAC modality Cis – gem 
Car – gem 
Other 
N (%) 205 (90) 
16 (7) 
8 (3) 
Cycles number Mean (range) 3 (1–6) 
Clinical 
response 
to NAC 
Yes 
No (stable disease) 
Progression 
Lack of tolerance 
Unknown 
N (%) 111 (48) 
42 (18) 
9 (4) 
31 (13) 
36 (16) 
 
105 patients (46%) had no AEs and 124 (54%) had AEs. Severe (grade 3–5) AEs 
were seen in 33% of patients, one death occurred and the operation was cancelled 
for four patients. Ninety-seven point five per cent of patients were eligible for RC 
after NAC treatment. The distribution of different AEs based on severity by CTCAE 
are presented in Table 9. Although one patient may suffer from many AEs, only the 
most severe AE / patient is reported in the table 9. 
Table 9.  Distribution of AEs during NAC treatment by CTCAE grade. 
Severity N=229 % 
0 105 46 
1 17 7 
2 31 14 
3 49 21 
4 26 11 
5 1 0.5 
 
The only statistically significant correlation with the pre-operatively available 22 
investigated variables was found between number of NAC cycles delivered and AEs. 
The correlation -0.37 refers to the low number of cycles P<0.001. This negative 
correlation was confirmed using FDR. All investigated variables and FDR-corrected 
correlations are presented in Table 10. 
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Table 10.  Correlation between 22 pre-operatively available variables and AEs during NAC. 
Variable Correlation coefficient P-value 
Number of cycles – 0.37 <0.001 
Renal disease 0.17 0.052 
Cerebrovascular disease – 0.13 0.205 
Rheumatoid disease – 0.13 0.229 
Peripheral arterial disease 0.12 0.239 
Myocardial infarction – 0.11 0.257 
Heart insufficiency 0.10 0.359 
Body mass index – 0.10 0.371 
Age 0.06 0.442 
Height 0.08 0.442 
ASA class 0.07 0.442 
Smoking, pack years 0.08 0.442 
Dementia 0.06 0.442 
Chronic pulmonary disease – 0.08 0.442 
Peptic ulcer 0.06 0.442 
Liver disease – 0.07 0.442 
Leukaemia – 0.07 0.442 
CCI score – 0.06 0.470 
Other solid tumour – 0.03 0.747 
ACCI 0.03 0.747 
Diabetes – 0.01 0.860 
Weight 0.00 0.960 
5.3 Effect of NAC on post-operative complications 
(Study III) 
We were able to collect data for 1402 RC patients in the database. Due to missing 
values, 17 patients were excluded and the total study population constituted 1385 
patients: 1171 in the RC-only population and 214 in the NAC+ RC population. The 
population was divided into cohorts: RC only, NAC + RC, RC only during NAC era 
and a cognitively matched cohort of RC patients from the pre-NAC era. Basic 
characteristics of the study population and cohorts is presented in Table 11. 
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Table 11.  Basic characteristics of the RC database population and study cohorts. 
   Entire cohort NAC era Matched cohort 
Variable   Total RC NAC+RC RC RC 
Patients  n 1385 1171 214 522 231 
Age Years Mean (SD) 67.9 (9.2) 68.5 (9.3) 64.5 (7.6) 69.5 (9.4) 65.0 (7.8) 
Gender 
Male 
% 
80 79 82 80 78 
Female 20 21 18 20 22 
BMI kg / m2 mean (SD) 26.5 (4.6) 26.5 (4.7) 26.3 (4.0) 26.5 (4.7) 26.3 (4.0) 
ASA 
1-2 
% 
38 37 44 29 52 
3 45 46 41 53 39 
4 4 5 1 5 2 
Unknown 12 12 14 13 7 
Histology 
Urothelial 
% 
87 85 94 88 84 
Other / 
unknown 13 15 6 12 16 
cTcategory 
MIBC 
% 
61 57 83 57 60 
NMIBC / 
unknown 39 43 17 43 40 
eGFR  median  69 68 72 65 75 
 
The total rate of complications was 61%: 65% of complications occurred in hospital 
and 35% after hospital discharge. Of the complications, Clavien 3–5 (severe) were 
seen in 56% and Clavien 1–2 (minor) in 44%. Mortality of RC was 4.0% in RC-only 
patients and 1.9 % in NAC + RC patients. NAC did not increase early post-operative 
complications in any of the investigated three cohorts. A detailed description of the 
risk of complications and the use of NAC in three different cohorts is presented in 
Table 12. 
  
 Table 12.  Risk of post-operative complications. NAC + RC was compared to RC only in three different patient cohorts and statistical analyses. 
Complications were presented with five-tiered Clavien grade (Dindo et al. 2004). 
Cohort Total study population NAC era Matched cohort 
No of patients N=1385 
RC=1171, NAC+RC=214 
N=736 
RC=552, NAC+RC=214 
N=445 
RC=231, NAC+RC=214 
Statistical method Multivariable logistic regression 
analysis 
Multivariable stratified logistic model 
with propensity score 
Multivariable stratified logistic 
regression analysis 
Complication 
group OR P-value OR P-value OR P-value 
All (1-5) 1.05 (0.73 to 1.50) 0.804 
0.73 
(0.48 to 1.12) 0.151 
1.32 
(0.89 to 1.98) 0.168 
Major (3-5) 0.69 (0.47 to 1.03) 0.068 
0.56 
(0.35 to 0.87) 0.010 
0.78 
(0.47 to 1.30) 0.339 
Death (5) 0.79 (0.29 to 2.13) 0.639 
0.62 
(0.18 to 2.1) 0.439 
0.57 
(0.11 to 2.87) 0.493 
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5.4 Identification of novel risk factors to predict 
post-operative mortality (Study IV) 
Twenty-two pre-operatively available variables presented in Table 10 were tested 
and only four had a statistically significant impact on risk of early post-operative 
death. These were: 
1) ASA (HR 2.63, 95% CI: 1.14–6.09, P = 0.02) 
2) ACCI (HR 4.02, 95% CI: 1.41–11.46, P = 0.009) 
3) Chronic heart insufficiency (HR 4.86, 95% CI: 2.18–10.81, P = 0.0001) 
4) Chronic pulmonary disease (HR 3.02, 95% CI: 1.46–6.26, P = 0.003) 
Chronic heart insufficiency and chronic pulmonary disease were identified as 
independent novel risk factors. 
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6 Discussion 
6.1 Evaluation of treatment response to NAC 
We evaluated primary tumours as shown in Study I and cannot recommend the use 
of PET-MRI in that context. Although PET-MRI was sensitive and did not 
understage any patient, adding PET to the current standard of staging is unnecessary, 
since pathological evaluation of BT and possible muscle invasion is more accurate 
and the decision on whether cystectomy is required or not cannot be based on 
imaging alone. The main interest was in the evaluation of treatment response to 
NAC. 
Complete pathological response (pT0 finding in RC specimen) is considered to 
reflect good prognosis (Petrelli et al. 2014). A NMIBC residual has not been reported 
to worsen the prognosis (Zargar et al. 2016). On the other hand, if there is no 
carcinoma left, why remove the bladder at all? This rationale has been behind MMT 
protocols. We evaluated treatment response to NAC with novel imaging (Study I). 
In MMT, imaging should have been replenished with TUR-BT and RT would have 
been given. Since TUR-BT does not include LND, re-staging of the bladder remains 
local; in LN evaluation, even in MMT, all depends on imaging. 
We selected 11C-acetate as a tracer. In a small comparison study it showed greater 
SUVmax in LNs, making it a logical selection for LN evaluation (Orevi et al. 2012). 
We chose MRI for anatomical imaging, because it is shown to be superior compared 
to CT in soft tissue (Barentsz et al. 1996). Each study subject received conventional 
CT after two cycles of NAC to exclude progression during NAC based on normal 
clinical praxis; by using MRI we were also able to avoid unnecessary radiation from 
repeated CT scans. 
Concerning MRI, the use of ultra-small paramagnetic particles of iron oxide 
(USPIO), Ferumoxtran has been interesting in terms of LN imaging, since it can 
also detect LNM in normal-sized LNs (Birkhauser et al. 2013). Approximately 30% 
of LNMs are however missed with this application, too (Birkhauser et al. 2013). 
Moreover, this MRI application is not clinically available, is very laborious and AEs 
can be seen in 11% of patients, which is not necessarily acceptable for a diagnostic 
investigation (Triantafyllou et al. 2013). USPIO-associated AEs can be considered 
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as minor – urticaria, hot flash, hypertension and headache, swelling of neck and nose 
and diarrhoea (Triantafyllou et al. 2013). 
We had only five RC patients with correlation to pathology. The sample size is 
not large enough to state whether PET-MRI is useful or not. It is however clear that 
with the use of 11C-acetate, forced urinary protocols, which have been shown to be 
beneficial in PET imaging utilising 18F-FDG, can be avoided. In a study by Harkirat 
et al. (2010) patients were orally hydrated with 1000-1500ml water and were asked 
to urinate at least three times before imaging took place (Harkirat et al. 2010). It is 
debatable whether to use a catheter. On the other hand, it is invasive and may cause 
urinary tract infection, as happened in three of our patients. Some of them could have 
possibly been avoided, if the urine was screened in advance. Then again, BC patients 
may have urinary incontinence and a 90-minute scan may cause discomfort, which 
can be avoided with catheter in place during imaging. Another benefit is that bladder 
volume is controlled in some way; we had 100cc in our study. Through repeated 
emptying and filling of the bladder we were able to standardise bladder volume, 
which is essential in image fusion, and without catheterisation this could have not 
been achieved. But discussion whether or not to use a catheter is speculative, since 
the main interest in functional imaging is LNM detection and in that no imaging 
modality can be considered reliable enough (Horn et al. 2016, Thoeny et al. 2014, 
Woo et al. 2018, Pichler et al. 2017, Birkhauser et al. 2013). 
6.2 Neoadjuvant chemotherapy-related 
complications 
Our studies showed that even severe AEs seldom prohibit execution of RC and that 
the use of NAC does not increase early (90d) post-operative mortality or severe 
complications (Study II & III). Patients with high ASA, high ACCI, existing severe 
cardiac dysfunction or severe respiratory disease are at the highest risk for early post-
operative mortality (Study IV). 
AEs are best described in RCTs. This can be clearly seen if we compare the 
Grade 1 AEs reported in our study vs. the rate reported in the prospective study by 
Iyer et al. We found only 7% of AEs compared to 90% of anaemia in Iyer at al. 
(2018). However, minor AEs seldom have a critical impact on the timing of RC, and 
concerning NAC treatment in MIBC, key RCTs are done with different regimens 
[(MVAC) Grossman et al. 2003, (MVC) Griffiths et al. 2011]. CG has been studied 
far less in the NAC setting. Khaled et. al. had 59 patients in their NAC arm, but 
eradicated 10 patients from final analysis. Grade III-IV haematological toxicities 
were reported in 14% of NAC patients and nausea and vomiting in 40% of patients. 
However, all received the scheduled regimen without dose adjustments (Khaled et 
al. 2014). Dose adjustments were studied in the phase II study by Anari et al. They 
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had to close early due to a higher than expected rate of vascular events with a dose-
dense regimen (Anari et al. 2018). CG has been compared to MVAC in one 
retrospective propensity matched study, where there was no difference between these 
two regimens (Galsky et al. 2015). In our study we did find that lack of tolerance is 
seen already after the first cycle (Study II). Although this was the only statistically 
significant finding, there was a statistically insignificant tendency with vascular 
diseases (chronic heart insufficiency and peripheral arterial disease) being more 
relevant than, for instance, diabetes (Study II). Renal impairment had a similar 
tendency, but this was already known. In a study by Dash et al., nearly 40% of 
patients, who could possibly benefit from NAC were platinum-ineligible (Dash et al. 
2006). 
AEs during NAC may prohibit execution of RC, as happened to 2.5% of patients 
in our study (Study II). This does not seem much, since in the landmark paper by 
Grossman et al, RC was not executed in 17% of patients treated with NAC for 
various reasons. On the other hand, in patients scheduled for RC only, an operation 
was performed for a similar proportion of patients (Grossman et al. 2003). However, 
this finding may explain why NAC does not seem to improve OS in the “real-life 
population” (Hanna et al. 2014). If the absolute benefit of NAC is 5%, but 2.5% 
NAC-treated patients do not receive surgery for whatever reasons, this simply 
undermines the total benefit of NAC and underlines the importance of proper patient 
selection for NAC. We do know that negative studies are not that easily published 
and that study populations differ from those of daily clinics material. And we also 
know that adequately planned retrospective or observational studies may be 
surprisingly similar to RCTs (Concato et al. 2000). So, our study, although 
retrospective, adds to data concerning NAC and especially CG NAC. 
The reported rate of post-operative mortality ranges from 2.1% (Afshar et al. 
2017) to 8.2% (Gandaglia et al. 2014). Our post-operative 90d mortality of RC was 
4%. In NAC + RC patients it was even lower (1.9%) mainly reflecting differences 
between the RC-only and NAC + RC populations. The total level of reported 
complications was 61%. This reflects the fact that even in a retrospective setting, 
data collection can be done with proper precision. While retrospective methods have 
their flaws, with current guideline recommendations (Witjes et al. 2017), it would be 
unethical to try to evaluate CG NAC in a prospective randomised setting. From this 
perspective, the observational method seems adequate and valid (Silverman 2009). 
In order to randomise retrospective material, we used a propensity score, which can 
be described as the probability of treatment assignment (Austin 2011). In comparison 
to RCT, where random allocation of treatments is often involved, but random 
selection of subjects is rarely involved (Little & Rubin 2000), matching patients with 
pre-treatment covariates may be considered acceptable. That is, if we consider 
covariates being variables whose values are not affected by the treatment assignment 
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and subsequent outcomes, and whose adjustment is essential to reduce or avoid bias 
(such as variables that are recorded before randomisation into treatment groups) 
(Little & Rubin 2000). Since other observational registry studies have shown a 
similar effect of NAC on post-operative complications (Gandaglia et al. 2014, 
Johnson et al. 2014, Tyson et al. 2014), we can safely say that CG NAC does not 
increase risk for early post-operative surgical complications.  
ASA is a known risk factor to predict post-operative complications or mortality 
after RC (Schultz et al. 2018, Korbee et al. 2019, Boström et al. 2009). But ASA 
comprises several factors that may not be equally important. We were able to detect 
that chronic heart insufficiency and chronic obstructive pulmonary disease were the 
most relevant risk factors, when risk factors were evaluated separately. Risk factors 
have been investigated before (Novotny et al. 2016). The most comorbid patients 
never receive RC. Our rationale was to identify those high ASA-class patients, who 
could be suitable for aggressive treatment, MMT, at least in the future. Even in the 
presence of high ASA, without evidence of vascular, kidney or liver disease, RC 
may be considered. 
6.3 Limitations of the studies 
Major limitations of the studies include the small sample size (Study I). However, 
no similar study has yet been done and justifying further research always starts with 
a small preliminary series to evaluate whether it is wise to continue research with the 
chosen modality. We feel that PET-MRI may have potential, especially when MMT 
protocols start to be adjusted in daily clinics in Finland. 
The retrospective nature of data collection and heterogeneity between RC centres 
(Studies II-IV) presents another limitation. But in order to create something new, 
we need information on the performance of current treatment algorithms. We 
acknowledge that NAC-associated AEs were collected by urologists and not by 
medical oncologists, who could probably have identified more AEs. The reported 
rate of minor AEs is not at all comparable to what it should be. However, the rate of 
more severe AEs, which have more impact on treatment, is in line with international 
series. Now, after a decade with national experience of the use of NAC, it was time 
to thoroughly evaluate where the level of treatment of MIBC in Finland is compared 
to international trends. We are happy to say, based on the numbers, that our results 
are not inferior to international trends, patient selection to NAC is successful and the 
mortality rates are acceptable. 
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6.4 Future directions 
The RC database will be utilised in many ways. There is evidence that OCNB is 
associated with more complications than NCIC diversion (van Hemelrijk et al. 
2013). We did not compare diversion methods, and this remains a matter for further 
research from the Finnish national radical cystectomy database. Centralisation of 
RCs has lowered perioperative mortality in Europe (Williams et al. 2019). The 
centre’s effect on mortality will be analysed. The effect on CSS with NAC will be 
investigated. The Finnish Cystectomy database data is combined with other registry 
data to further analyse mortality. 
A machine-learning methodology has already been utilised. Digitalisation and 
computer aided work is a growing industry. We will continue utilising artificial 
intelligence to create more personalised treatment protocols for our patients. 
A PET-MRI protocol is established and can be utilised when MMT is started in 
Finland. The imaging data will be combined with repeated TUR-BT and liquid 
biopsy information. We have also investigated MRI only to create a faster MRI 
protocol, which will be useful in the future. This MRI-only study should be reported 
during 2020 and we are ready to go with MMT. 
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7 Summary/Conclusions 
11C-acetate PET-MRI alone is insufficient in NAC treatment response evaluation. A 
combination of hybrid imaging, accurate histopathology and liquid biopsies is worth 
investigating in the future if bladder-preserving strategies are considered. 
Patient selection for NAC treatment in Finland is justified. Severe AEs occurring 
during NAC treatment seldom prohibit the execution of RC and the level of minor 
AEs is acceptable.  
Fear of the influence of NAC on post-operative complications should not 
preclude its use. If NAC is tolerated, it does not increase post-operative surgical 
complications. These results should encourage to increase the use of NAC in MIBC 
patients. 
A high ASA class should not automatically avert patients from receiving RC in 
the absence of cardiac or chronic respiratory disease. A more personalised approach 
to evaluating fitness for surgical operation is needed. On the other hand, bladder-
preserving MMT strategies should be developed to aid those unfit for RC. 
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